The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive chemoradiotherapy.
 
Marc Oliva Bernal
Travel, Accommodations, Expenses - Merck
Other Relationship - Merck
 
Shao Hui Huang
No Relationships to Disclose
 
Rachel Taylor
No Relationships to Disclose
 
Jie Su
No Relationships to Disclose
 
Wei Xu
No Relationships to Disclose
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Raymond Woo-Jun Jang
Consulting or Advisory Role - Ipsen; Novartis
Research Funding - AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Andrew Bayley
No Relationships to Disclose
 
Ali Hosni
No Relationships to Disclose
 
Meredith Elana Giuliani
Honoraria - AstraZeneca
Research Funding - Lilly
Travel, Accommodations, Expenses - Elekta
 
Jolie Ringash
No Relationships to Disclose
 
Scott Victor Bratman
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.
 
John Cho
No Relationships to Disclose
 
Jonathan Crawford Irish
No Relationships to Disclose
 
John Waldron
No Relationships to Disclose
 
Ilan Weinreb
No Relationships to Disclose
 
John Kim
No Relationships to Disclose
 
Brian O'Sullivan
Consulting or Advisory Role - IBA; Merck; Merck; Pfizer
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Loxo; Merck; MorphoSys; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Anna Spreafico
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Surface Oncology; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Merck